Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy

Anti-EGFR targeted therapy is a potent strategy in the treatment of metastatic colorectal cancer (mCRC) but activating mutations in the KRAS gene are associated with poor response to this treatment. Therefore, KRAS mutation analysis is employed in the selection of patients for EGFR-targeted therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gattenlöhner, S., Etschmann, B., Kunzmann, V., Thalheimer, A., Hack, M., Kleber, G., Einsele, H., Germer, C., Müller-Hermelink, H. -K.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837901/
https://www.ncbi.nlm.nih.gov/pubmed/20300583
http://dx.doi.org/10.1155/2009/831626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837901/
https://www.ncbi.nlm.nih.gov/pubmed/20300583
http://dx.doi.org/10.1155/2009/831626

Ejemplares similares